Search Results for 'immunotherapy'
-
Breaking News | Collaborations & Alliances | Drug Development
Celgene Licenses Two Dragonfly Immunotherapy Candidates
The licenses represent the first two of four hematological cancer targets from the companies' June 2017 collaboration12.13.18
-
Breaking News | Drug Development | Drug Discovery | Industry News
Celgene, Dragonfly Expand Immunotherapy Alliance
Celgene has the option to license exclusive rights to products using Dragonfly's TriNKET platform for four new targets11.14.18
-
Bio News | Breaking News | Collaborations & Alliances | Industry News | Information Technology | R&D
Ultimovacs Acquires Immuneed's Immunotherapy Unit
The NOK 50.4mm deal includes a rename of the business unit to Ultimovacs AB08.30.18
-
Bio News | Breaking News | Drug Development | Drug Discovery | Facilities | Industry News | Laboratory Testing | R&D
PolyU, Axis Therapeutics Partner for Immunotherapy
The joint immunotherapy center will aim to conduct collaborative research on cancer immunotherapy in Hong KongVideos
-
Collaborations & Alliances | Drug Development | Drug Discovery
IsoPlexis, Nektar Therapeutics in Immunotherapy Alliance
Will employ IsoCode Chip's single-cell functional profiling in collaboration with Nektar to profile effects of NKTR-21406.26.18
-
Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development
AbbVie, Turnstone Biologics Enter Immunotherapy Agreement
Gains option to license three of Turnstone's next-gen oncolytic viral immunotherapies10.11.17
-
Drug Development | Industry News
Thermo Fisher Forms Cancer Immunotherapy Consortium
Aims to drive adoption of next-generation sequencing research to identify prognostic biomarkers08.31.17
-
Drug Development | Industry News | Trials & Filings
-
Biologics, Proteins, Vaccines
Will Immunotherapy Knock Out Cancer?
Innovative immunotherapy companies discuss with WuXi AppTec what’s next for this rapidly developing field ahead of BIO 2017.Online Exclusives06.14.17
-
Clinical Trials | Drug Development
Rethinking Immunotherapy Clinical Endpoints in Oncology Studies
Chris Smyth and Joy Yucaitis of Novella Clinical evaluate criteria, regulations, and limitationsChris Smyth, Ph.D. and Joy Yucaitis, Novella Clinical 10.28.16
